Cologuard

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer detection test Cologuard. This is a patient-friendly, non-invasive stool-based DNA test that users can...

Analysts at Bank of America turned incrementally bullish on EXACT Sciences Corporation (NASDAQ: EXAS) after the company reported a clean beat and raise quarter. The firm's Anne Edelstein maintains a Buy rating on Exact Sciences' stock with a price target boosted from $56 to $58. Exact Sciences'...

Following a series of investor meetings with EXACT Sciences Corporation's (NASDAQ: EXAS) CEO and chief financial officer, Cowen said it has come back with fortified confidence in the outlook for upside relative to current Street financial expectations. Not All Are Optimistic This is in...

EXACT Sciences Corporation (NASDAQ: EXAS) plummeted over 7 percent Monday on a Citron Research report predicting a 40-percent short-term value concession and long-term drop to a near-zero single digit. Citron's most important report in YEARS. $EXAS to trade short term $20. Long term much lower...

Humana Inc (NYSE: HUM) has finally come around after showing intransigence in including EXACT Sciences Corporation (NASDAQ: EXAS)'s Cologuard test in its coverage policy. Humana's Commentary A Humana spokesperson told Benzinga exclusively that starting January 1, 2017, "Humana's Commercial members...

U.S. stocks continued to sell off on Friday on higher than usual volume. Semiconductor stocks were hit hard following Microchip's profit warning and cautious sector-wide comments. The rest of the tech sector was weak, especially "momentum" and high-beta stocks as the Nasdaq index...